Ohtake S
Second Department of Surgery, Hokkaido University School of Medicine, Sapporo, Japan.
Hokkaido Igaku Zasshi. 1997 Jan;72(1):43-57.
On experimental portal vein replacement of mongrel dogs with high porosity EPTFE grafts (fibril length: 60 microns) wrapped in omental pedicle flap, it has been reported that healing process is promoted. But it is not clear on the antithrombotic properties of the newly growing endothelial cells on prosthetic vascular grafts. PGI2 and NO are known as antithrombotic factors that restrain the agglutination of platelets. We evaluated PGI2 and NO production from the newly growing endothelial cells on prosthetic vascular grafts. High porosity EPTFE grafts were implanted at the portal veins of mongrel dogs. After 3 months we removed the grafts and tried to procure the new growing endothelial cells by trypsinization and culture them. We confirmed by using Dil-Ac-LDL that endothelial-like cells on prosthetic vascular grafts were as same as the endothelial cells. As control cells, we used the endothelial cells of canine portal vein and infra vena cava. The basal PGI2 production from each cells and the thrombin-stimulated production of PGI2 were measured by radioimmuno assay. Thrombin concentration was established at 2 unit/ml. On the basal PGI2 production there was no significant difference between the grafts and the portal veins, and between the grafts and the infra vena cava. The PGI2 production of the grafts increased significantly by stimulating with thrombin. On the thrombin-stimulated production, there was no significant difference between the grafts and the portal veins, and between the grafts and the infra vena cava. NO production of the grafts was measured by the griess reaction. On NO production there was no significant difference between the grafts and the portal veins. But the grafts produced significantly more NO than the infra vena cava (P < 0.05). This study suggests that the newly growing endothelial cells on the prosthetic vascular grafts may have the antithrombotic properties equal to the endothelial cells on the portal vein and the infra vena cava.
在杂种犬的实验性门静脉置换中，使用包裹在网膜蒂瓣中的高孔隙率EPTFE移植物（纤维长度：60微米），据报道愈合过程得到促进。但尚不清楚人工血管移植物上新生长的内皮细胞的抗血栓形成特性。前列环素（PGI2）和一氧化氮（NO）是已知的抑制血小板凝集的抗血栓形成因子。我们评估了人工血管移植物上新生长的内皮细胞产生PGI2和NO的情况。将高孔隙率EPTFE移植物植入杂种犬的门静脉。3个月后取出移植物，通过胰蛋白酶消化获取新生长的内皮细胞并进行培养。我们使用Dil-Ac-LDL证实人工血管移植物上的内皮样细胞与内皮细胞相同。作为对照细胞，我们使用犬门静脉和下腔静脉的内皮细胞。通过放射免疫测定法测量每个细胞的基础PGI2产生量以及凝血酶刺激后的PGI2产生量。凝血酶浓度设定为2单位/毫升。在基础PGI2产生量方面，移植物与门静脉之间以及移植物与下腔静脉之间没有显著差异。凝血酶刺激后移植物的PGI2产生量显著增加。在凝血酶刺激后的产生量方面，移植物与门静脉之间以及移植物与下腔静脉之间没有显著差异。通过格里斯反应测量移植物的NO产生量。在NO产生量方面，移植物与门静脉之间没有显著差异。但移植物产生的NO明显多于下腔静脉（P<0.05）。本研究表明，人工血管移植物上新生长的内皮细胞可能具有与门静脉和下腔静脉内皮细胞相当的抗血栓形成特性。
